CN118678964A - Ig样融合蛋白及其用途 - Google Patents

Ig样融合蛋白及其用途 Download PDF

Info

Publication number
CN118678964A
CN118678964A CN202280091480.XA CN202280091480A CN118678964A CN 118678964 A CN118678964 A CN 118678964A CN 202280091480 A CN202280091480 A CN 202280091480A CN 118678964 A CN118678964 A CN 118678964A
Authority
CN
China
Prior art keywords
fragment
domain
seq
polypeptide
mutation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280091480.XA
Other languages
English (en)
Chinese (zh)
Inventor
K·奥维德
G·登克贝格
S·里夫
Y·皮祖尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Canupe Immunotherapy Co
Original Assignee
Canupe Immunotherapy Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Canupe Immunotherapy Co filed Critical Canupe Immunotherapy Co
Publication of CN118678964A publication Critical patent/CN118678964A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70571—Receptors; Cell surface antigens; Cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/286—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against neuromediator receptors, e.g. serotonin receptor, dopamine receptor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Toxicology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN202280091480.XA 2021-12-13 2022-12-13 Ig样融合蛋白及其用途 Pending CN118678964A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163288782P 2021-12-13 2021-12-13
US63/288,782 2021-12-13
PCT/IL2022/051321 WO2023112028A1 (en) 2021-12-13 2022-12-13 Ig-like fusion proteins and use thereof

Publications (1)

Publication Number Publication Date
CN118678964A true CN118678964A (zh) 2024-09-20

Family

ID=86774007

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280091480.XA Pending CN118678964A (zh) 2021-12-13 2022-12-13 Ig样融合蛋白及其用途

Country Status (6)

Country Link
US (1) US20250059255A1 (https=)
EP (1) EP4447993A4 (https=)
JP (1) JP2024547218A (https=)
CN (1) CN118678964A (https=)
CA (1) CA3240617A1 (https=)
WO (1) WO2023112028A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120500348A (zh) * 2022-12-13 2025-08-15 卡努佩免疫治疗公司 用于治疗重症肌无力的Ig样融合蛋白
WO2025030000A1 (en) * 2023-08-01 2025-02-06 Merida Biosciences, Inc. Molecules for controlling autoimmune response
AU2024318666A1 (en) * 2023-08-01 2026-01-22 Merida Biosciences, Inc. Molecules for controlling autoimmune response
WO2025126210A1 (en) * 2023-12-13 2025-06-19 Canopy Immuno-Therapeutics Ltd. Ig-like fusion proteins for treating musk myasthenia gravis
WO2025126216A1 (en) * 2023-12-13 2025-06-19 Canopy Immuno-Therapeutics Ltd. Improved acetylcholine receptor molecules and use thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100719020B1 (ko) * 2005-09-28 2007-05-17 광주과학기술원 재조합 아세틸콜린 수용체 폴리펩티드, 폴리펩티드 유도체및 이를 유효성분으로 포함하는 중증근무력증 치료제
JP4857396B1 (ja) * 2011-04-13 2012-01-18 日本製薬株式会社 融合蛋白質
WO2016044137A2 (en) * 2014-09-15 2016-03-24 The Trustees Of The University Of Pennsylvania Acetylcholine receptor-specific immunosuppressive compositions and methods of treatment of myasthenia gravis

Also Published As

Publication number Publication date
JP2024547218A (ja) 2024-12-26
WO2023112028A1 (en) 2023-06-22
EP4447993A1 (en) 2024-10-23
CA3240617A1 (en) 2023-06-22
EP4447993A4 (en) 2026-04-01
US20250059255A1 (en) 2025-02-20

Similar Documents

Publication Publication Date Title
JP7476298B2 (ja) Ｍａｇｅ－ａに特異的に結合する抗原結合タンパク質
US20250059255A1 (en) Ig-like fusion proteins and use thereof
US20230203200A1 (en) Recruiting agent further binding an mhc molecule
ES2293748T3 (es) Moleculas de fijacion poliespecificas y usos de las mismas.
ES3008567T3 (en) Recombinant antibody molecule and its use for target cell restricted t cell activation
US6410690B1 (en) Therapeutic compounds comprised of anti-Fc receptor antibodies
CN111867612A (zh) 抗PDL1、IL-15和TGF-β受体组合分子
CN110799528A (zh) 基于多聚体il-15的分子
CN116981470A (zh) T细胞调节多肽和其使用方法
CA3026652A1 (en) Anti-tnfrsf25 antibodies
US20250376502A1 (en) Ig-like fusion proteins for treating graves disease
KR20250166188A (ko) Tnfr2 결합 폴리펩타이드 및 이의 용도의 방법
CN120500348A (zh) 用于治疗重症肌无力的Ig样融合蛋白
WO2018138185A1 (en) Novel t cell receptors and immune therapy using the same for the treatment of cancer and infectious diseases
WO2023031943A2 (en) Cd28 shedding blocking agents
KR20230052279A (ko) 비-천연 발생 변형 fc 수용체에 특이적으로 결합하는 igg의 인간 비-천연 발생 변형 fc 영역
WO2025126210A1 (en) Ig-like fusion proteins for treating musk myasthenia gravis
WO2025126216A1 (en) Improved acetylcholine receptor molecules and use thereof
JP7829127B2 (ja) 抗原結合ドメインおよびサイトカイン三量体ドメインを含む融合タンパク質
CN121443630A (zh) 用于治疗膜性肾病的ig样融合蛋白
KR20130033273A (ko) 항 ｉｇｆ-1ｒ 단일클론 항체와 ｉｌ-2를 포함하는 융합 단일클론 항체 및 이를 포함하는 암치료용 조성물
WO2025126202A1 (en) P32-specific antibodies and car t cells for the treatment of p32 expressing tumors
EP4680630A1 (en) Ig-like fusion proteins for treating pemphigus vulgaris and foliaceus
WO2024231931A1 (en) Ig-like fusion proteins for treating immune thrombocytopenia
TW202438523A (zh) 靶向ＰＤ－Ｌ１和中和Ｇａｓ６之融合蛋白及其用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination